PF-03550096 is a
drug that acts as a potent
agonist for the CB2cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by
Pfizer in 2008 as a medication for
irritable bowel syndrome,[1] but has only progressed to animal studies.[2]
PF-03550096 is a
drug that acts as a potent
agonist for the CB2cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by
Pfizer in 2008 as a medication for
irritable bowel syndrome,[1] but has only progressed to animal studies.[2]